The signing of the Gaining Antiobiotic Incentives Now (GAIN) Act should benefit companies pursuing the development of novel antibiotics. Once approved, these products will enjoy an additional five years of marketing exclusivity. Companies that should benefit from this Act include OPTR, MDCO, and CBST
CBST. Not yet approved, so there is time for proinvestor to go long. :))
Optimer will have an even broader client base, already on its way, with ACA.